See the full text of the patent here: http://patents.com/us-7944465.html
Zecotek Photonics Inc. (ZMS – TSX Venture, W1I – Frankfurt),a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that patent number 7,944,465 has been granted by the U.S. Patent and Trademark Office for its glasses-free 3D auto-stereoscopic display system. The U.S. patent grant adds to a growing number of global patents and patent applications which serves to significantly strengthen Zecotek’s worldwide patent position in its innovative photonics technology.
“Protection of our intellectual property is of the highest priority to Zecotek and receiving the U.S. patent for our glasses-free 3D display system represents a key step in the commercialization of this unique technology,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “With a number of significant technical barriers preventing the development of a true 3D display, the U.S. patent protects our innovative glasses-free approach to 3D display technology. Our 3D auto-stereoscopic display offers a real volumetric 3D viewing experience with one of the widest viewing angles and the highest resolution compared to competing technologies. We will continue to pursue full commercialization of this technology with a strategic partner.”
The new patent covers the use of equipment for the reproduction of static and moving 3D stereo representations with the capability of recording and transmitting stereo representations of 3D scenes. Zecotek’s “patented” Real-Time 3D Display System is based on the auto-stereoscopic principle, but with substantial innovative. It has the capability of simultaneously presenting to multiple users both 3D and 2D images on the same screen with separate views and at different viewing angles. The 3D display system provides comfortable conditions for viewing a volumetric representation without eye strain. The viewing of such 3D images does not require the use of any supplementary means such as glasses, does not drastically limit the position of the viewer with respect to the display, and allows simultaneous viewing of the 3D display by many viewers from a sufficiently wide field of view.
Patents have now been granted to Zecotek for its 3D display system in the United States and Australia. Patents have been filed and are pending in Japan, China, Korea, India, Russia and major countries in Europe.
About Zecotek’s Real-Time 3D Display System
Zecotek’s 3D Display System is based on the auto-stereoscopic principle, but with substantial innovative and patented improvements and represents a new and unique generation of 3D displays. It has the capability of simultaneously presenting 3D and 2D images on the same screen, and for separate views at different viewing angles. Zecotek’s true, auto-stereoscopic 3D2D display system requires no eyewear and has an effective viewing angle of 40 degrees with 90 concurrent perspectives allowing for multiple views at the same time. Another unique feature of the Zecotek system is constant motion parallax within the viewing angle. Motion parallax eliminates the sense of imbalance and dizziness during normal observation which can occur with polarized and shutter glasses used with other commercial systems.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.
See the press release here: http://www.usetdas.com/TDAS/NewsArticle.aspx?NewsID=17602